Stock Events

FibroGen 

€1.59
3
+€0+0% Today

Statistics

Day High
1.59
Day Low
1.59
52W High
-
52W Low
-
Volume
1,350
Avg. Volume
-
Mkt Cap
1.87B
P/E Ratio
-5.17
Dividend Yield
-
Dividend
-

Upcoming

Earnings

26FebExpected
Q2 2022
Q3 2022
Q4 2022
Q1 2023
Q2 2023
Q3 2023
Next
-0.98
-0.8
-0.62
-0.44
Expected EPS
-0.44
Actual EPS
N/A

People Also Follow

This list is based on the watchlists of people on Stock Events who follow 1FG.F. It's not an investment recommendation.

About

FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases that is in Phase III clinical development for the treatment of anemia in chronic kidney disease in the United States and Europe; and in Phase II/III development in China for anemia associated with myelodysplastic syndromes. It is also developing Pamrevlumab, a human monoclonal antibody that inhibits the activity of connective tissue growth factor that is in Phase III clinical development for the treatment of idiopathic pulmonary fibrosis, pancreatic cancer, liver fibrosis, and diabetic kidney disease, as well as Phase II trial for the treatment of Duchenne muscular dystrophy. The company has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. FibroGen, Inc. was incorporated in 1993 and is headquartered in San Francisco, California.
Show more...
CEO
Mr. James A. Schoeneck
Employees
599
Country
US
ISIN
US31572Q8087
WKN
000A12EZ0

Listings